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Abbreviations HWE: Hardy–Weinberg equilibrium
To the Editor: Some concerns have been raised that the
analytical methods we used for genotyping may be responsible
for the striking differences observed in the distribution of the
genotypes of the PAX4 A1168C SNP, which deviated from
Hardy–Weinberg equilibrium (HWE). In our certified
laboratory (ISO/IEC 17025, accreditation STS286) both
genotypingmethods used (RFLP and allelic discrimination)
were validated as described below.
Pre-analytical phase To check the influence of sample
preparation (DNA extraction), transport and storage on the
results, DNA extractions were performed on ten EDTA
blood samples. DNA extraction was performed immedi-
ately after collection, 48 h after storage at room temperature
in the dark (mimicking the average shipment time), and
from blood spots on filter paper. All extractions were
frozen, kept at −20°C for 7 days and then thawed before
analysis. The DNA extractions were performed as de-
scribed previously [1].
Analytical phase (1) Precision. To check reproducibility,
we performed ten analyses of the ten EDTA blood samples
on the same day. We also assessed day-to-day precision by
performing a single analysis of each of the ten samples on
five different days. Laboratory precision was checked by a
single analysis of each of the ten samples by two different
operators. (2) Accuracy. Five DNA samples, received from
an associated laboratory, with known genotype (unknown
to us) were each assayed on the same day. (3) Re-finding.
Although the results are qualitative, in order to exclude
artefacts due to DNA concentration, ten samples were
diluted 1:5, 1:10 and 1:100 and analysed on the same day.
Linearity and detection limits were not tested in this qual-
itative assay.
Our acceptance criterion was set at <5% discrepancy. In
case of a discrepancy either within one of the methods or
between methods the discordant samples were analysed by
sequencing of PCR‐amplified exonic fragments of exon 9.
As a reference, three DNAs representing the three geno-
types (A/A, A/C and C/C) were used in every series. The
reference sequences were CH236947.1 andAF043978. The
discrepancy between the results of RFLP and sequencing
was 3%, whereas that between allelic discrimination and
sequencing was 2%.
All the case–control study samples were analysed by
both methods. As an internal control the same three samples
with genotype confirmed by sequencing for the three
variants (A/A, A/C and C/C) plus a blank (no DNA) were
used in every series. To check the validity of the method, we
re-analysed the same ten samples per population every
fourth series (every 30×4=120 analyses for RFLP, and
83×4=332 analyses for allelic discrimination). Since the
batches of reagents are sufficient for 200 and 600 RFLP and
allelic discrimination reactions, respectively, this procedure
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evaluates the influence of batch differences on the results.
The discrepancy rate was comparable to that found in the
validation series (2.9% for RFLP and 2.1% for allelic
discrimination).
Post-analytical phase (interpretation) To decrease the pos-
sibility of biased interpretation of the results, we used two
approaches. Firstly, all samples were analysed in a blind
fashion—the samples were coded by numbers only. The
code was revealed after completion of the analysis of the
entire population (Swiss or German). For the German
population, operator and code-breaker were two different
individuals. Secondly, to minimise congruency errors (cor-
respondence case-result) due to data transfer errors (e.g.
errors in the ordering of data in the Excel tables), the two
populations were analysed separately and the results were
listed in separate tables. The chance that such errors occur
repeatedly and still generate the same trend in distribution
should be very low.
We realised that although we found an association
between PAX4 variants and type 1 diabetes, the data are not
in HWE. Of particular concern were the ‘excess heterozy-
gotes’ in the control group of both populations. Since
deviation from HWE in this case is most likely caused by
genotyping errors, we decided to address this issue using a
third genotyping method, namely, sequencing (in addition
to RFLP and allele discrimination, as described above and
in [1]) to confirm our results. Sequencing produced similar
results, suggesting that the genotyping was correct. The
most probable explanation for this phenomenon is that the
polymorphism represents a heterozygote advantage, one of
the known causes of deviation from HWE (together with
outbreeding, mutations, gene migration, genetic drift and
non-random mating). This is not an isolated phenomenon
as it has been previously described and discussed [2–6].
That the A/C genotype might confer a functional advantage
is also confirmed by our expression studies. Although
rather unlikely, there is always the possibility that a cryptic
population stratification (a systematic difference in ances-
try rather than association of genes with disease) might
influence our case–control data and that the correlation
between type 1 diabetes and PAX4 observed in our popu-
lations, although representative of the average populations
of these countries, might not be reproduced in other groups.
Similarly, PAX4 variants have been linked to type 2 dia-
betes in some ethnic groups but not in others [7, 8]. Thus,
as underlined by A. Paterson, it is important to investigate
other populations [9]. In this light, the data by Maier et al.
[10], which are based on family studies, are very in-
teresting. We are therefore currently studying other pop-
ulations (Italian patients and control subjects) to find out
whether the ‘Swiss-German’ variant correlation will be
confirmed.
Although diabetes remains a multifactorial disease and
can by no means be ascribed to a variation in a single gene,
the role of PAX4 in the regeneration of beta cells is
supported by our work [11] and indicates a link, at least in
certain populations, between PAX4 defects and defects in
the regeneration of beta cells. Further studies, such as those
outlined by M. Tiedge in his commentary on our study
[12], are necessary and are currently underway to identify
other components of this pathophysiological network.
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